Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment

New England Journal of Medicine - Tập 363 Số 18 - Trang 1704-1714 - 2010
Guillaume Paré1,2,3,4, Shamir R. Mehta1,4, Salim Yusuf1,2,4, Sonia S. Anand1,2,4, Stuart J. Connolly1,4, Jack Hirsh1,4, Katy L. Simonsen5, Deepak L. Bhatt6, Keith A.A. Fox7, John W. Eikelboom1,4
1Departments of Medicine, McMaster University
2Epidemiology, McMaster University
3Pathology, McMaster University
4Population Health Research Institute, Hamilton Health Sciences, McMaster University
5Bristol-Myers Squibb, New York
6Veterans Affairs Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School — all in Boston
7Centre for Cardiovascular Science, Edinburgh University and Royal Infirmary, Edinburgh

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1056/NEJMoa0901301

10.1056/NEJMoa010746

10.1016/S0140-6736(08)61845-0

10.1056/NEJMoa0809171

10.1001/jama.2009.1232

10.1161/CIRCULATIONAHA.109.885194

10.1053/euhj.2000.2474

10.1016/S0140-6736(01)05701-4

10.1016/j.ahj.2005.06.026

10.1016/j.pharmthera.2007.09.004

10.1016/j.jacc.2008.12.044

10.1161/CIRCULATIONAHA.109.866533

10.1161/01.CIR.0000051362.96946.15

10.1056/NEJMoa0808227

10.1111/j.1538-7836.2009.03500.x

10.1016/j.clpt.2005.10.002

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 363 Số 18

1704-1714

Thông tin tác giả